Cell

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells

Retrieved on: 
вторник, мая 21, 2024
Physiology, University of Calgary, Therapy, DDW, Doctor of Philosophy, Infection, Cumming School of Medicine, Conditional sentence, University, Movement, GALT, Cell, IVM, Biotechnology, Inflammatory bowel disease, Pharmaceutical industry

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation of new data, using Spinning Disk Intravital Microscopy (IVM), that provides real-time, in vivo visualization of the impact of α4β7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues (GALT). These data were presented in a poster session at Digestive Disease Week (DDW) 2024 meeting.

Key Points: 
  • This real-time footage and the associated data for B cell movement clearly demonstrate that MT-108, a potent and selective small molecule α4β7 inhibitor, leads to increased velocity and flux of rolling lymphocytes.
  • The onset and extent of α4β7 inhibition can be visualized by the increased velocity of B cells when comparing the lymphocyte movement prior to compound administration.
  • In the absence of inhibitor, cells are slowed by their binding of α4β7 with the ligand MAdCAM-1.
  • “These new data demonstrate not only that a small molecule α4β7 inhibitor drives changes comparable to a monoclonal antibody but also provide stunning real time in vivo visualization of this activity.

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial

Retrieved on: 
вторник, мая 21, 2024
Paper, Patient, Doctor of Philosophy, HD, Stem cell, Ageing, Cell, Mouse, GPC, Nature Biotechnology, MD, Neuron, Neurology, Biotechnology, Astrocyte, Brain, Glia, Pelizaeus–Merzbacher disease, Vaccine

SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain.” This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) – the cells that give rise to the glial support cells of the brain – were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the development of SC379, Sana’s pluripotent stem cell-derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders.

Key Points: 
  • These data establish an additional proof-of-concept for the development of SC379, Sana’s pluripotent stem cell-derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders.
  • “It is remarkable to see that healthy human glial cells can engraft and function in vivo, and succeed in outcompeting resident glial cells, thereby eradicating the diseased cells from the brain of the mice,” said Steve Harr, Sana’s President and Chief Executive Officer.
  • Over time, the group found that the healthy WT cells overtook the HD cells and repopulated the striatum with healthy cells (54 weeks, P
  • The data demonstrated that the younger hGPCs rapidly infiltrated the striatum and eventually replaced the older hGPCs, leading to a substantial recolonization of the tissue (P

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
понедельник, мая 20, 2024
Cream, Asset purchase agreement, Patient, PTCH1, Darier's disease, Prescription, United States district court, Patent, First, Nevoid basal-cell carcinoma syndrome, Clinical trial, FDA, Abbreviated New Drug Application, NESS, Skin, Bank statement, Psoriasis, Dermatology, Neoplasm, Genetic disorder, BCC, Cell, Compassion, Research, SMO, Autosome, District court, Carcinoma, Sol–gel process, Pharmaceutical industry

Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suffering from an ultra-rare disease.

Key Points: 
  • Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suffering from an ultra-rare disease.
  • According to IQVIA, the annual market sales in the 12 months ended in January 2024 for Zoryve® Cream were approximately $ 95 million.
  • We also initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease, with results expected in H1/2025.
  • As a result, previously reported revenue for the first quarter of 2023 was revised as reflected in the below income statement.

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

Retrieved on: 
понедельник, мая 20, 2024
PLUR, Prevalence, Cell, Breast milk, Breast, Quality of life, Medicine, Pharmaceutical industry

By combining Pluri’s cutting-edge 3D cell-expansion technology with Wilk’s expertise in developing cultured human breast and animal milk products, the strategic collaboration will use the components of breast milk to develop a unique medical food intended for the elderly on a commercial scale.

Key Points: 
  • By combining Pluri’s cutting-edge 3D cell-expansion technology with Wilk’s expertise in developing cultured human breast and animal milk products, the strategic collaboration will use the components of breast milk to develop a unique medical food intended for the elderly on a commercial scale.
  • Medical foods for the elderly are specifically formulated and designed to meet the unique nutritional needs and health concerns of older adults.
  • “Wilk Technologies is committed to unlocking the potential of cell-based medical foods,” said Avital Beck, Ph.D., CEO of Wilk Technologies.
  • “This collaboration with Wilk Technologies perfectly aligns with our vision as we harness the unique properties of breast milk cells to create medical food solutions for a rapidly growing elderly population.

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

Retrieved on: 
понедельник, мая 20, 2024
Cell, Doctor of Philosophy, ISCT, Research and development, Translation, Clinical trial, International Society, Leber congenital amaurosis, Vaccine, Annual general meeting, BLA, MAA, LCA, PDT, Pharmaceutical industry

“I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay.

Key Points: 
  • “I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay.
  • Attendees can participate in robust debates, collaborate on developing solutions to sector challenges, and join conversations advancing the field of cell and gene therapy.
  • The OCU400 Phase 3 liMeliGhT clinical trial is currently underway and on track to meet the Company’s 2026 BLA and MAA approval targets.
  • OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

Retrieved on: 
понедельник, мая 20, 2024
Exosome, EV, Nanoparticle, Biomedical Research, Flow cytometry, Mark II, Disease, EVS, Signal, Research, Cell, Seminal vesicles, Virus, Fluorescence, Medical imaging

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora ™ and Cytek Northern Lights ™ cell analysis systems.

Key Points: 
  • FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora ™ and Cytek Northern Lights ™ cell analysis systems.
  • With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for cell analysis, making them the preferred choice among researchers and clinicians.
  • Typically, flow cytometers have been unable to detect particles smaller than 500 nm, limiting their use to the study of cells and larger particles.
  • For availability details and more information on Cytek’s new ESP Detection Option on the Cytek Aurora and Northern Lights systems, please visit https://cytekbio.com/pages/esp .

Hexagon Purus and Hino Trucks Introduce Tern: A Pioneering Electric Heavy-Duty Truck

Retrieved on: 
понедельник, мая 20, 2024
ACT, Arctic tern, Partnership, Booth, Marketing, Interview, GVWR, Safety, EVP, Cell, Hino Motors, 2600-series (CTA), Rail transport

This innovative semi-tractor leverages Hexagon Purus' years of development of zero-emission drivetrains for heavy-duty trucks and represents a driver-preferred option for fleets that are electrifying practical routes.

Key Points: 
  • This innovative semi-tractor leverages Hexagon Purus' years of development of zero-emission drivetrains for heavy-duty trucks and represents a driver-preferred option for fleets that are electrifying practical routes.
  • A product of the new long-term agreement between Hexagon Purus and Hino Trucks, valued at up to approximately $2 billion, Tern is designed to deliver a seamless transition to electrification for the U.S. commercial vehicle sector.
  • Manufactured in Hexagon Purus' new facility in Dallas, Texas, the Tern RC8 is scheduled for serial production in late 2024.
  • “Our partnership with Hexagon Purus introduces a highly reliable Class 8, 4x2 tractor option into the electric truck market, catering to a wide range of applications.

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Retrieved on: 
четверг, мая 16, 2024
Doctor of Philosophy, Toxicity, Asos, Therapy, LNC, Small RNA, Macrophage, Cell, Poster, Lecture, Vaccine

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.

Key Points: 
  • BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
  • The poster, “Intracellular Delivery of Small Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies,” was presented by Hui Liu, PhD, Chief Technology Officer of Matinas, and is available here .
  • The poster discusses in vitro studies demonstrating the avid uptake of LNC formulations of various cytokine-targeted small oligonucleotides in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
  • These characteristics make LNCs a highly promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides.”

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
среда, мая 15, 2024
Patient, Cell, Systemic scleroderma, Movement, Lupus, Pemphigus vulgaris, Food, Myopathy, Investment, Letter, CD19, FDA, Disease, MuSK protein, MPV, Conference, Cytokine release syndrome, Dermatology, Congress, Growth, Gene, Immunoglobulin therapy, Potential, Juvenile dermatomyositis, Cyclophosphamide, Dermatomyositis, Symposia, EULAR, IIM, Society, Health Canada, A1, Observation, Research, Clinical trial, DLT, Myositis, Annual general meeting, CRS, Pharmaceutical industry

PHILADELPHIA, May 15, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • PHILADELPHIA, May 15, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • In March 2024, Cabaletta announced the first patient had been dosed in the Phase 1/2 RESET-Myositis trial.
  • Cabaletta expects to report initial clinical data from the Phase 1/2 RESET-SSc™ trial in the second half of 2024.
  • Cabaletta expects to report initial clinical data from the Phase 1/2 RESET-MG™ trial in the second half of 2024.

NanoXplore Reports Results for its Q3-2024

Retrieved on: 
вторник, мая 14, 2024
Analysis, Corporation, Accounting, EDT, Bank statement, MD, Acquisition, Cell, G&A, Plastic, Bookkeeping

Other income increased from $848,380 in the last year period to $983,554 in the current period.

Key Points: 
  • Other income increased from $848,380 in the last year period to $983,554 in the current period.
  • Results of operations may include certain unusual and other items which have been separately disclosed, where appropriate, in order to provide a clear assessment of the underlying Corporation results.
  • NanoXplore will hold a webcast tomorrow, May 15, 2024, at 8:30 am EDT to review its Q3-2024.
  • Soroush Nazarpour, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event.